YJEFN3 and colorectal carcinoma: These distinct expression landscapes highlight that ABHD4 and YJEFN3 may contribute to CRC progression through different cellular mechanisms within the TME, emphasizing the importance of considering cell-type specificity in biomarker interpretation and therapeutic targeting.